Intensified intensity-modulated radiotherapy in anal cancer with prevalent HPV p16 positivity

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 21, Issue 37

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Gastroenterol. Oct 7, 2015; 21(37): 10688-10696
Published online Oct 7, 2015. doi: 10.3748/wjg.v21.i37.10688

Table 2 Patients characteristics n (%)

SCC: Squamous cell cancer; MMC: Mitomycin–C; 5-FU: 5-fluorouracil.

Citation: Belgioia L, Vagge S, Agnese D, Garelli S, Murialdo R, Fornarini G, Chiara S, Gallo F, Bacigalupo A, Corvò R. Intensified intensity-modulated radiotherapy in anal cancer with prevalent HPV p16 positivity. World J Gastroenterol 2015; 21(37): 10688-10696
URL: https://www.wjgnet.com/1007-9327/full/v21/i37/10688.htm
DOI: https://dx.doi.org/10.3748/wjg.v21.i37.10688

Belgioia L, Vagge S, Agnese D, Garelli S, Murialdo R, Fornarini G, Chiara S, Gallo F, Bacigalupo A, Corvò R. Intensified intensity-modulated radiotherapy in anal cancer with prevalent HPV p16 positivity. World J Gastroenterol 2015; 21(37): 10688-10696 [PMID: 26457030 DOI: 10.3748/wjg.v21.i37.10688]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.